| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 91 | 2023 | 15694 | 1.740 |
Why?
|
| Carcinoma, Ductal, Breast | 12 | 2017 | 1216 | 0.860 |
Why?
|
| Mastectomy | 23 | 2020 | 1534 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2021 | 10035 | 0.640 |
Why?
|
| Radiotherapy, Conformal | 5 | 2019 | 902 | 0.580 |
Why?
|
| Capecitabine | 1 | 2017 | 388 | 0.550 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2013 | 222 | 0.530 |
Why?
|
| Mastectomy, Segmental | 16 | 2015 | 1026 | 0.480 |
Why?
|
| Lymphedema | 4 | 2023 | 239 | 0.460 |
Why?
|
| Yoga | 4 | 2017 | 78 | 0.460 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2015 | 2370 | 0.430 |
Why?
|
| Breast Cancer Lymphedema | 2 | 2023 | 38 | 0.430 |
Why?
|
| Breast Neoplasms, Male | 4 | 2008 | 229 | 0.400 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.380 |
Why?
|
| Radiotherapy Dosage | 19 | 2017 | 3842 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 24 | 2019 | 3890 | 0.340 |
Why?
|
| Carcinoma, Lobular | 6 | 2017 | 611 | 0.340 |
Why?
|
| Female | 93 | 2023 | 141928 | 0.290 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2011 | 509 | 0.280 |
Why?
|
| Middle Aged | 64 | 2021 | 86204 | 0.260 |
Why?
|
| Breast | 7 | 2021 | 1344 | 0.260 |
Why?
|
| Lymphatic Metastasis | 19 | 2019 | 4844 | 0.260 |
Why?
|
| Disease-Free Survival | 18 | 2017 | 10001 | 0.260 |
Why?
|
| Combined Modality Therapy | 24 | 2021 | 8865 | 0.260 |
Why?
|
| Quality of Life | 8 | 2023 | 4532 | 0.250 |
Why?
|
| Mastectomy, Modified Radical | 4 | 2010 | 70 | 0.250 |
Why?
|
| Carcinoma in Situ | 4 | 2011 | 487 | 0.240 |
Why?
|
| Radiation Injuries | 6 | 2015 | 1411 | 0.240 |
Why?
|
| Adult | 60 | 2017 | 77950 | 0.230 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2003 | 27 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 15 | 2021 | 4975 | 0.230 |
Why?
|
| Doxorubicin | 15 | 2017 | 3005 | 0.220 |
Why?
|
| Retrospective Studies | 44 | 2021 | 37905 | 0.220 |
Why?
|
| Humans | 100 | 2023 | 261506 | 0.220 |
Why?
|
| Electrons | 2 | 2010 | 168 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2017 | 15862 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 14 | 2015 | 2231 | 0.200 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 143 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2015 | 674 | 0.200 |
Why?
|
| Aged | 45 | 2021 | 70117 | 0.190 |
Why?
|
| Patient Positioning | 2 | 2015 | 195 | 0.190 |
Why?
|
| Lymphatic Irradiation | 4 | 2009 | 133 | 0.190 |
Why?
|
| Lymph Node Excision | 10 | 2023 | 1959 | 0.180 |
Why?
|
| Treatment Outcome | 30 | 2021 | 32848 | 0.180 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2017 | 85 | 0.180 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 1046 | 0.170 |
Why?
|
| Proton Therapy | 4 | 2020 | 1577 | 0.170 |
Why?
|
| Radiotherapy | 8 | 2017 | 1824 | 0.170 |
Why?
|
| Axilla | 10 | 2013 | 902 | 0.170 |
Why?
|
| Clavicle | 5 | 2010 | 65 | 0.160 |
Why?
|
| Neoplasm Staging | 20 | 2019 | 13658 | 0.160 |
Why?
|
| Sternum | 1 | 2019 | 100 | 0.160 |
Why?
|
| Fatigue | 4 | 2017 | 1239 | 0.150 |
Why?
|
| Prospective Studies | 11 | 2023 | 12873 | 0.150 |
Why?
|
| Tissue Expansion | 1 | 2017 | 71 | 0.150 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.150 |
Why?
|
| Sleep Wake Disorders | 2 | 2017 | 348 | 0.150 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 87 | 0.140 |
Why?
|
| Age Factors | 8 | 2011 | 5377 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 799 | 0.130 |
Why?
|
| Adenocarcinoma | 4 | 2014 | 7789 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2010 | 726 | 0.130 |
Why?
|
| Lymph Nodes | 6 | 2021 | 2967 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 423 | 0.130 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 14889 | 0.130 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 135 | 0.130 |
Why?
|
| Mammaplasty | 2 | 2017 | 780 | 0.130 |
Why?
|
| Meditation | 1 | 2016 | 73 | 0.130 |
Why?
|
| Radiology Information Systems | 1 | 2015 | 114 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2008 | 436 | 0.120 |
Why?
|
| Survivors | 2 | 2017 | 1031 | 0.120 |
Why?
|
| Documentation | 1 | 2015 | 207 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2013 | 2104 | 0.120 |
Why?
|
| Depression | 4 | 2017 | 1715 | 0.120 |
Why?
|
| Algorithms | 3 | 2014 | 3890 | 0.110 |
Why?
|
| Survival Analysis | 11 | 2009 | 9180 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 3472 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6207 | 0.110 |
Why?
|
| Risk Assessment | 7 | 2011 | 6869 | 0.110 |
Why?
|
| Emollients | 1 | 2011 | 12 | 0.110 |
Why?
|
| Petrolatum | 1 | 2011 | 11 | 0.100 |
Why?
|
| Radiodermatitis | 1 | 2011 | 75 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 128 | 0.100 |
Why?
|
| Inhalation | 1 | 2011 | 42 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2017 | 1529 | 0.100 |
Why?
|
| Movement | 2 | 2011 | 556 | 0.090 |
Why?
|
| Aged, 80 and over | 13 | 2017 | 29902 | 0.090 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 168 | 0.090 |
Why?
|
| Survival Rate | 10 | 2021 | 12221 | 0.090 |
Why?
|
| Paclitaxel | 3 | 2011 | 1996 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 291 | 0.090 |
Why?
|
| Fluorouracil | 5 | 2017 | 1944 | 0.090 |
Why?
|
| Mammography | 3 | 2014 | 1010 | 0.090 |
Why?
|
| Gynecomastia | 1 | 2008 | 13 | 0.090 |
Why?
|
| Mastectomy, Radical | 2 | 2005 | 39 | 0.080 |
Why?
|
| Cohort Studies | 9 | 2021 | 9244 | 0.080 |
Why?
|
| Body Mass Index | 4 | 2010 | 2203 | 0.080 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 493 | 0.080 |
Why?
|
| Time Factors | 10 | 2017 | 12926 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2011 | 598 | 0.080 |
Why?
|
| Breast Diseases | 1 | 2010 | 201 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2014 | 1171 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2015 | 929 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2008 | 1350 | 0.080 |
Why?
|
| Skin | 2 | 2010 | 1259 | 0.080 |
Why?
|
| Analysis of Variance | 6 | 2008 | 2307 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1215 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 7551 | 0.070 |
Why?
|
| Cyclophosphamide | 5 | 2017 | 3001 | 0.070 |
Why?
|
| Parotid Gland | 1 | 2006 | 112 | 0.070 |
Why?
|
| Radiography | 5 | 2010 | 1904 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2008 | 240 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 155 | 0.070 |
Why?
|
| Muscle Stretching Exercises | 2 | 2017 | 17 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 176 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2006 | 82 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 4849 | 0.070 |
Why?
|
| SEER Program | 4 | 2014 | 1000 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2011 | 665 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2008 | 204 | 0.070 |
Why?
|
| Pregnancy | 5 | 2013 | 7573 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2008 | 388 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 1303 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 361 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 3981 | 0.070 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 295 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 4298 | 0.070 |
Why?
|
| Calcinosis | 1 | 2008 | 423 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 598 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2006 | 665 | 0.060 |
Why?
|
| Texas | 6 | 2015 | 6311 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2009 | 674 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2016 | 388 | 0.060 |
Why?
|
| Carcinoma | 2 | 2006 | 2578 | 0.060 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2004 | 126 | 0.060 |
Why?
|
| Risk Factors | 8 | 2015 | 17523 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2006 | 518 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 701 | 0.050 |
Why?
|
| United States | 7 | 2017 | 15433 | 0.050 |
Why?
|
| Prognosis | 9 | 2017 | 21713 | 0.050 |
Why?
|
| Regression Analysis | 4 | 2006 | 1546 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2015 | 2316 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2011 | 1391 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 482 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2006 | 1271 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 5112 | 0.050 |
Why?
|
| Tamoxifen | 4 | 2006 | 876 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 1162 | 0.050 |
Why?
|
| Incidence | 3 | 2009 | 5673 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1323 | 0.050 |
Why?
|
| Body Image | 1 | 2021 | 141 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 852 | 0.040 |
Why?
|
| Male | 11 | 2020 | 123000 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 671 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 294 | 0.040 |
Why?
|
| Radiation Oncology | 2 | 2015 | 529 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2021 | 309 | 0.040 |
Why?
|
| Adolescent | 4 | 2009 | 31252 | 0.040 |
Why?
|
| Clinical Trials as Topic | 5 | 2010 | 3719 | 0.040 |
Why?
|
| Smoking | 1 | 2008 | 2440 | 0.040 |
Why?
|
| Pneumonia | 1 | 2004 | 751 | 0.040 |
Why?
|
| Photons | 2 | 2013 | 507 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2004 | 1415 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 291 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2006 | 1105 | 0.040 |
Why?
|
| Scattering, Radiation | 2 | 2010 | 316 | 0.040 |
Why?
|
| Actigraphy | 1 | 2017 | 54 | 0.040 |
Why?
|
| Epirubicin | 1 | 2017 | 157 | 0.040 |
Why?
|
| Tissue Expansion Devices | 1 | 2017 | 62 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5767 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2004 | 977 | 0.040 |
Why?
|
| Meaningful Use | 1 | 2015 | 17 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 32 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1945 | 0.030 |
Why?
|
| Computer Systems | 1 | 2015 | 106 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2010 | 342 | 0.030 |
Why?
|
| Logistic Models | 2 | 2015 | 3441 | 0.030 |
Why?
|
| Supine Position | 1 | 2015 | 46 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 1258 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2011 | 1987 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 915 | 0.030 |
Why?
|
| Medicare | 2 | 2010 | 860 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 2518 | 0.030 |
Why?
|
| China | 1 | 2016 | 606 | 0.030 |
Why?
|
| Dyssomnias | 1 | 2014 | 7 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 413 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1374 | 0.030 |
Why?
|
| Heart | 2 | 2011 | 1223 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 5687 | 0.030 |
Why?
|
| Counseling | 1 | 2016 | 381 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.030 |
Why?
|
| Registries | 2 | 2014 | 2170 | 0.030 |
Why?
|
| Receptors, Estrogen | 3 | 2006 | 2086 | 0.030 |
Why?
|
| Prone Position | 1 | 2013 | 56 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 612 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 2403 | 0.030 |
Why?
|
| Saliva | 1 | 2014 | 231 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 3230 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 866 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 667 | 0.030 |
Why?
|
| Breast Implants | 1 | 2017 | 391 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2014 | 289 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2004 | 5178 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 672 | 0.030 |
Why?
|
| Pregnancy Outcome | 2 | 2006 | 643 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2011 | 257 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 925 | 0.020 |
Why?
|
| Internet | 1 | 2015 | 706 | 0.020 |
Why?
|
| Young Adult | 4 | 2011 | 21445 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 409 | 0.020 |
Why?
|
| Proportional Hazards Models | 3 | 2004 | 4988 | 0.020 |
Why?
|
| British Columbia | 1 | 2010 | 24 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 5437 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 690 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 978 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1742 | 0.020 |
Why?
|
| Cellulitis | 1 | 2010 | 72 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 37 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 70 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 1183 | 0.020 |
Why?
|
| Diet | 1 | 2016 | 1440 | 0.020 |
Why?
|
| Hematoma | 1 | 2010 | 160 | 0.020 |
Why?
|
| Abscess | 1 | 2010 | 177 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2010 | 259 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 99 | 0.020 |
Why?
|
| Ultrasonics | 1 | 2008 | 69 | 0.020 |
Why?
|
| Respiration | 1 | 2010 | 447 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5539 | 0.020 |
Why?
|
| Health Resources | 1 | 2009 | 168 | 0.020 |
Why?
|
| Palliative Care | 1 | 2019 | 2037 | 0.020 |
Why?
|
| Mucins | 1 | 2008 | 285 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 671 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 276 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2002 | 5542 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 627 | 0.020 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 2006 | 77 | 0.020 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2006 | 89 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 11538 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Nipples | 1 | 2005 | 132 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2003 | 2594 | 0.020 |
Why?
|
| Child Development | 1 | 2006 | 255 | 0.020 |
Why?
|
| Overweight | 1 | 2007 | 484 | 0.010 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2004 | 88 | 0.010 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 14289 | 0.010 |
Why?
|
| Remission Induction | 1 | 2009 | 3569 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6100 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 1143 | 0.010 |
Why?
|
| Gestational Age | 1 | 2006 | 1069 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 726 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1301 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 1533 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2008 | 1555 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1544 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 1226 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2007 | 1620 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1547 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Catheterization | 1 | 2004 | 410 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 629 | 0.010 |
Why?
|
| Carcinoma, Medullary | 1 | 2003 | 248 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 739 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 4892 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 827 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 1656 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2004 | 1014 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 980 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 3260 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 3151 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 1392 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 2173 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 6682 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 2055 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 7548 | 0.010 |
Why?
|
| Obesity | 1 | 2007 | 2884 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 4758 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 10331 | 0.000 |
Why?
|
| Child | 1 | 2006 | 29154 | 0.000 |
Why?
|
| Animals | 1 | 2008 | 59536 | 0.000 |
Why?
|